[1]张至惠,李 沐.附子理中汤加减对脾肾阳虚型胃癌术后化疗患者血清肿瘤标志物的影响*[J].陕西中医,2019,(2):171-173，177.
　ZHANG Zhihui,LI Mu..Fuzi Lizhong decoction on serum tumor markers in patients with gastric cancer undergoing postoperative chemotherapy[J].,2019,(2):171-173，177.
点击复制

附子理中汤加减对脾肾阳虚型胃癌术后化疗患者血清肿瘤标志物的影响*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年2期
页码:
171-173，177
栏目:
临床研究
出版日期:
2019-02-05

文章信息/Info

Title:
Fuzi Lizhong decoction on serum tumor markers in patients with  gastric cancer undergoing postoperative chemotherapy
文章编号:
DOI: 10.3969/j.issn.10007369.2019.02.009
作者:
张至惠1; 李 沐2
1.河南省驻马店市中医院（驻马店 463000）；2.河南省人民医院（郑州 450003）
Author(s):
ZHANG Zhihui; LI Mu.
Zhumadian Hospital of Traditional Chinese Medicine (Zhumadian 463000)
关键词:
附子理中汤;  胃癌 ;  脾肾阳虚型;  肿瘤标志物;  HE4; 血清重组穿透素3
Keywords:
Key words Fuzi Lizhong decoction ;  Gastric cancer ;  Spleen and kidney yang deficiency type;  serum tumor markers;  HE4;  Pentraxin3
分类号:
R735.2
文献标志码:
A
摘要:
摘 要 目的：探究附子理中汤加减对胃癌（脾肾阳虚型）术后化疗患者血清肿瘤标志物和生命质量的影响。方法：采用计算机随机数字法将132例胃癌（脾肾阳虚型）患者分为观察组和对照组各66例。对照组患者在术后予以支持对症治疗和化疗治疗（奥沙利铂+卡培他滨），观察组患者在对照组基础上予以附子理中汤加减治疗。比较两组患者近期疗效差异，观察治疗前后生活质量\[Karnofsky评分（KPS）\]、T细胞（CD4+Th17、CD4+CD25+Treg、Th17/Treg）、血清肿瘤标记物\[细胞角蛋白19血清片段211（CYFRA211）、人附睾蛋白4（HE4）、血清重组穿透素3（Pentraxin3）、甲状腺转录因子1（TTF1）\]等指标变化情况，记录不良反应发生率。结果：观察组患者治疗总有效率高于对照组（P＜0.05）；治疗12周后，两组患者CD4+Th17水平、血清CYFRA211、HE4、Pentraxin3、TTF1水平均较治疗前降低，且观察组低于对照组（P＜0.05），KPS评分、CD4+CD25+Treg、Th17/Treg水平较治疗前升高，且观察组高于对照组（P＜0.05）；两组患者总不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：脾肾阳虚型胃癌患者术后化疗时服用附子理中汤加减可明显改善患者临床症状和生活质量，阻止肿瘤进展，提高细胞免疫，且安全性高。
Abstract:
Abstract Objective：To explore the effects of addition and subtraction of Fuzi Lizhong decoction on serum tumor markers and quality of life in postoperative chemotherapy patients with gastric cancer (spleen and kidney yang deficiency type). Methods：132 cases of patients with gastric cancer (spleen and kidney yang deficiency type) were divided into observation group and control group according to computer random number method，with 66 cases in each group. Control group was treated with support symptomatic treatment and chemotherapy (oxaliplatin+capecitabine) after operation，and observation group was given addition and subtraction of Fuzi Lizhong decoction on the basis of control group. The shortterm efficacy was compared between the two groups. The quality of life \[Karnofsky score (KPS)\]，T cells (CD4+Th17，CD4+CD25+Treg，Th17/Treg)，serum tumor markers \[cytokeratin 19 serum fragments 211 (CYFRA211)，human epididymis protein 4 (HE4)，serum recombinant penetin3 (Pentraxin3)，thyroid transcription factor1 (TTF1)\] were observed before and after treatment，and the incidence rate of adverse reactions was recorded. Results：The total effective rate of treatment in observation group was higher than that in control group (P＜0.05). After 12 weeks of treatment，the levels of CD4+Th17，serum CYFRA211，HE4，Pentraxin3 and TTF1 in the two groups were lower than those before treatment，and the levels in observation group were lower than those in control group (P＜0.05)，and the KPS score and levels of CD4+CD25+Treg and Th17/Treg were higher than those before treatment，and the indexes in observation group were higher than those in control group (P＜0.05). There was no significant difference in the incidence rate of adverse reactions (P＞0.05). Conclusions：Addition and subtraction of Fuzi Lizhong decoction in postoperative chemotherapy of patients with gastric cancer (spleen and kidney yang deficiency type) can significantly improve the clinical symptoms and quality of life，prevent tumor progression，and promote cellular immunity，and it has high safety.

参考文献/References:

\[1\] 任明丽,周群燕.扶正活血饮Ⅱ号方对胃癌术后患者胃肠功能、生活质量及机体免疫功能的影响[J] .陕西中医,2017,38(12):16761678.
[2] 冯谢敏,胡海峰,胡云峰,等.参芪扶正注射液对胃癌根治术后化疗患者免疫功能及生活质量的影响[J] .陕西中医,2017,38(10):14071408.
[3] 閤 谦,吴 骋,童林军,等.RECIST1.1、PERCIST1.0、WHO及EORTC用于评价结直肠癌肝脏转移化疗后疗效的对比[J] .中华核医学与分子影像杂志,2017,37(9):559563.
[4] 胡小苗,向进见.腹腔镜辅助远端胃癌D2根治术的疗效及安全性探讨[J] .中国内镜杂志,2017,23(4):7680.
[5] 王晓君,吴 乾.中医健脾祛瘀法治疗胃癌的应用与疗效评价[J] .中国药物与临床,2018,18(1):117118.
[6] 陈婉珍,徐婷婷,朱方石,等.益气健脾化积方对胃癌化疗气虚血瘀证患者生活质量影响的随机双盲安慰剂对照试验[J] .中医杂志,2017,58(9):759762.
[7] 唐 伟,马 燕,陈久红,等.胃癌癌前病变患者中医体质类型与证型相关性研究[J] .安徽中医药大学学报,2017,36(4):3033.
[8] 李 玲,王凤梅,刘永琦,等.归芪白术方辅助治疗胃癌患者的临床研究[J] .中国临床药理学杂志,2017,33(13):11841187.
[9] 蓝 芳,谢丽萍,谢永祥,等.加味附子理中汤对药物性急性肾损伤患者T淋巴细胞亚群及血管性假血友病因子的影响[J] .临床肾脏病杂志,2017,17(6):336339.〖ZK)〗
[10] 林冬莉,华 雅,徐展琼,等.赖氏"通元针法"结合附子理中汤加味治疗卒中后麻痹性肠梗阻[J] .中国中医药信息杂志,2018,25(3):115118.
[11] 葛国岚.温法治疗小儿长期发热疾病临证举隅[J] .浙江中医药大学学报,2017,41(7):605608.
[12] 侯建媛.附子理中汤合四神丸治疗脾肾阳虚型腹泻型肠易激综合征疗效及对直肠黏膜蛋白酶激活受体的影响[J] .现代中西医结合杂志,2018,27(18):20222025.

相似文献/References:

[1]王亚明,肖 锟△,刘晓玲,等.附子理中汤加减合温针灸联合西药治疗脾肾阳虚型血脂异常疗效研究*[J].陕西中医,2020,(6):770.[doi:DOI:10.3969/j.issn.10007369.2020.06.019]

备注/Memo

备注/Memo:
*河南省科技攻关计划项目（201703489）
更新日期/Last Update: 2019-03-13